EGFR and small cell lung carcinoma: Based on our findings that ERK, MSK/RSK, and CBP/p300 play critical roles in the regulation of NETFs in SCLC cell lines, we treated EGFR/TP53/RB1 triple-mutant H1975 cells with inhibitors for EGFR, ERK, MSK/RSK, and/or CBP/p300 to inhibit effectors that suppress NE differentiation with the anticipation that it would eventually cause histological transformation into SCLC.